ATE235057T1 - Cell test und diagnostischer kit für alzheimer- erkrankung - Google Patents

Cell test und diagnostischer kit für alzheimer- erkrankung

Info

Publication number
ATE235057T1
ATE235057T1 AT95935666T AT95935666T ATE235057T1 AT E235057 T1 ATE235057 T1 AT E235057T1 AT 95935666 T AT95935666 T AT 95935666T AT 95935666 T AT95935666 T AT 95935666T AT E235057 T1 ATE235057 T1 AT E235057T1
Authority
AT
Austria
Prior art keywords
alzheimer
cells
disease
differences
diagnostic kit
Prior art date
Application number
AT95935666T
Other languages
English (en)
Inventor
Daniel L Alkon
Rene Etcheberrigaray
Christopher S Kim
Yi-Fan Han
Tom J Nelson
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE235057T1 publication Critical patent/ATE235057T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AT95935666T 1994-09-26 1995-09-26 Cell test und diagnostischer kit für alzheimer- erkrankung ATE235057T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/312,202 US5976816A (en) 1993-05-03 1994-09-26 Cell tests for alzheimer's disease
PCT/US1995/012433 WO1996010182A1 (en) 1994-09-26 1995-09-26 Cell tests and diagnostic index for alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE235057T1 true ATE235057T1 (de) 2003-04-15

Family

ID=23210345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95935666T ATE235057T1 (de) 1994-09-26 1995-09-26 Cell test und diagnostischer kit für alzheimer- erkrankung

Country Status (8)

Country Link
US (2) US5976816A (de)
EP (2) EP1310798A2 (de)
JP (1) JPH10506990A (de)
AT (1) ATE235057T1 (de)
AU (1) AU714118B2 (de)
CA (1) CA2200963A1 (de)
DE (1) DE69529992D1 (de)
WO (1) WO1996010182A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
AU719038B2 (en) 1996-03-29 2000-05-04 Trustees Of Boston University Methods for diagnosing and treating Alzheimer's disease
US6248222B1 (en) * 1998-09-08 2001-06-19 Acm Research, Inc. Methods and apparatus for holding and positioning semiconductor workpieces during electropolishing and/or electroplating of the workpieces
WO2001077686A2 (en) * 2000-04-05 2001-10-18 Neurologic, Inc. Cellular calcium responce for diagnosis of alzheimer's disease
EP1925315A3 (de) * 2001-02-27 2009-11-18 Blanchette Rockefeller Neurosciences Institute Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung
ATE394115T1 (de) * 2001-02-27 2008-05-15 Brni Neurosciences Inst Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
ES2301754T3 (es) * 2002-02-12 2008-07-01 University Of Utah Research Foundation Analisis de pruebas multiples de amplificaciones de acidos nucleicos en tiempo real.
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20040049134A1 (en) * 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
AU2003289859A1 (en) * 2002-11-11 2004-06-03 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of arl7 for alzheimer's disease
WO2004110963A2 (en) * 2003-05-29 2004-12-23 Pettegrew Jay W Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
CA2582270A1 (en) * 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease
US20070054890A1 (en) * 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
US20090029873A1 (en) * 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
CA2659242C (en) 2006-07-28 2015-08-11 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
KR20140049054A (ko) * 2007-02-09 2014-04-24 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 두부 외상으로 유발된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과
JP2011529344A (ja) * 2008-07-28 2011-12-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の刺激誘発ゲノムプロフィールマーカー
EP3586839A1 (de) 2008-07-28 2020-01-01 Blanchette Rockefeller Neurosciences, Institute Pkc-aktivierende verbindungen zur behandlung von neurodegenerativen erkrankungen
WO2011034580A2 (en) * 2009-09-18 2011-03-24 University Of Houston Small peptide modulators of potassium channel trafficking
BR112012007557A2 (pt) * 2009-10-02 2017-05-02 Blanchette Rockefeller Neurosciences Inst alterações anormais de processamento de isozimas de pkc em células periféricas da doença de alzheimer
EP2483684B1 (de) * 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Fibroblast wachstumsmuster zur diagnose der alzheimer-krankheit
WO2011102907A1 (en) * 2010-02-22 2011-08-25 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
EP3026420B1 (de) * 2011-05-12 2017-11-01 Florin V. Chirila Periphere diagnostische verfahren zum screening von morbus alzheimer mit beta-amyloid und interzellularer kommunikation
US20140235496A1 (en) 2011-10-05 2014-08-21 Blanchette Rockefeller Neurosciences Drive Stimulus-elicited genomic profile markers of a neurodegenerative condition
US9163032B2 (en) 2011-11-13 2015-10-20 Blanchette Rockefeller Neurosciences Insitute Esters of DCPLA and methods of treatment using the same
WO2020176573A1 (en) * 2019-02-26 2020-09-03 NeuroDiagnostics LLC Methods for diagnosing alzheimer's disease based on cell growth rate, size and protein amount

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
JPH03505868A (ja) * 1988-04-08 1991-12-19 マサチユセツツ・インスチチユート・オブ・テクノロジー 神経性疾患を治療するための方法及び組成物
IL90189A0 (en) * 1988-06-01 1989-12-15 Squibb & Sons Inc Pharmaceutical compositions containing a benzazepine-type calcium channel blocker
JPH069693A (ja) * 1992-01-23 1994-01-18 Eiken Chem Co Ltd アルツハイマー病関連蛋白
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
US5580748A (en) * 1993-05-03 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tests for alzheimers disease

Also Published As

Publication number Publication date
EP0783695B1 (de) 2003-03-19
US6080582A (en) 2000-06-27
CA2200963A1 (en) 1996-04-04
AU3759295A (en) 1996-04-19
EP1310798A2 (de) 2003-05-14
JPH10506990A (ja) 1998-07-07
DE69529992D1 (de) 2003-04-24
AU714118B2 (en) 1999-12-16
WO1996010182A1 (en) 1996-04-04
US5976816A (en) 1999-11-02
EP0783695A1 (de) 1997-07-16

Similar Documents

Publication Publication Date Title
DE69529992D1 (de) Cell test und diagnostischer kit für alzheimer-erkrankung
ATE155888T1 (de) Zell-test für alzheimersche krankheit
WO1999058981A3 (en) Diagnostic tests for alzheimer's disease
WO2000066762A3 (en) Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
MX9707889A (es) Metodo y dispositivo para diagnosticar y distinguir dolor de pecho en inicio temprano del mismo.
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
EP0836723A4 (de) Virtuelles medizinisches instrument zum midizinischen diagnostiktesten von patienten
ATE325343T1 (de) Diagnose und behandlung von arthritischen erkrankungen
DE69631738D1 (de) Medizinische implantierbare Vorrichtung für elektrochemische Messungen von Bluteigenschaften
ES2151880T3 (es) Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
NO953770L (no) Analysemetode
Gusman et al. Human salivary gland-specific daily variations in histatin concentrations determined by a novel quantitation technique
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
Arnvig et al. Neurotoxic effects of heavy lead exposure determined with psychological tests
Loas et al. Anhedonia in the deficit syndrome of schizophrenia
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
NO986218L (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100
Seller et al. Magnesium metabolism in hypertension
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
Zachariae et al. An evaluation of dose/unit area and time as key factors influencing the elicitation capacity of methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) in MCI/MI‐allergic patients
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
Petitti et al. Physiologic measures in men with and without vasectomies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties